Chelation treatment for autism spectrum disorders: A systematic review

Research in Autism Spectrum Disorders

Volumn 7, Issue 1, 2013, Pages 49-55

  Davis, Tonya N ^a   O'Reilly, Mark ^b   Kang, Soyeon ^b   Lang, Russell ^c   Rispoli, Mandy ^d   Sigafoos, Jeff ^e   Lancioni, Giulio ^f   Copeland, Daelynn ^a   Attai, Shanna ^a   Mulloy, Austin ^g  

^a BAYLOR UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TEXAS STATE UNIVERSITY   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^f UNIVERSITY OF BARI   (Italy)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Autism spectrum disorders; Chelation; Detoxification; Metal toxicity

Indexed keywords

CHELATING AGENT; CLONIDINE; DEXAMPHETAMINE; LEUPRORELIN; METHYLPHENIDATE;

ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHELATION THERAPY; DIET SUPPLEMENTATION; DIET THERAPY; HUMAN; INTERPERSONAL COMMUNICATION; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; REVIEW; SOCIAL ADAPTATION; STEREOTYPY; SYSTEMATIC REVIEW;

EID: 84864932029     PISSN: 17509467     EISSN: 18780237     Source Type: Journal    
DOI: 10.1016/j.rasd.2012.06.005     Document Type: Review

References (34)

1. J.B. Adams, M. Baral, E. Geis, J. Mitchell, J. Ingram, and A. Hensley Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A - Medical results BMC Clinical Pharmacology 9 2009 1 22
2. J.B. Adams, M.M. Baral, E.E. Geis, J.J. Mitchell, J.J. Ingram, and A.A. Hensley Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results BMC Clinical Pharmacology 9 17 2009 1 9
3. American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders-fourth edition, text revision 2000 American Psychiatric Association Washington, DC
4. R.A. Beauchamp, T.M. Willis, T.G. Betz, J. Villanacci, R.D. Leiker, and L. Rozin Deaths associated with hypocalcemia from chelation therapy - Texas, Pennsylvania, and Oregon, 2003-2005 Journal of the American Medical Association 295 2006 2131 2133
5. M.J. Brown, T. Willis, B. Omalu, and R. Leiker Deaths resulting from hypocalcemia after administration of edentate disodium: 2003-2005 Pediatrics 118 2006 534 536
6. Centers for Disease Control and Prevention Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008 Morbidity and Mortality Weekly Report. CDC Surveillance Summaries 61 SS03 2012 1 19
7. I.L. Cohen, and V. Sudhalter The PDD Behavior Inventory 2005 Psychological Assessment Resources, Inc. Lutz, FL
8. A. Doja, and W. Roberts Immunizations and autism: A review of the literature The Canadian Journal of Neurological Sciences 33 2006 341 346 (Pubitemid 44951981)
9. T. Eppright, J. Sanfacon, and E. Horwitz Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: A possible relationship Missouri Medicine 93 3 1996 136 138
10. J.W. Harrington, L. Rosen, A. Garnecho, and P.A. Patrick Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice Journal of Developmental & Behavioral Pediatrics 27 2006 S156 S161
11. L.J. Heflin, and R.L. Simpson Interventions for children and youth with autism: Prudent choices in a world of exaggerated claims and empty promises. Part I: Intervention and treatment option review Focus on Autism and Other Developmental Disabilities 13 1998 194 211
12. I. Hertz-Picciotto, P.G. Green, L. Delwiche, R. Hansen, C. Walker, and I.N. Pessah Blood mercury concentrations in CHARGE study children with and without autism Environmental Health Perspectives 118 2010 161 166
13. D. Geier, and M. Geier A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders Neuroendocrinology Letters 27 2006 833 838 (Pubitemid 46138649)
14. A.E. Golnik, and M. Ireland Complementary alternative medicine for children with autism: A physician survey Journal of Autism and Developmental Disorders 39 2009 996 1005
15. V.A. Green, K.A. Pituch, J. Itchon, A. Choi, M. O'Reilly, and J. Sigafoos Internet survey of treatments used by parents of children with autism Research in Developmental Disabilities 27 2006 70 84 (Pubitemid 41785473)
16. C. Lord, M. Rutter, P.C. DiLavore, and S. Risi Autism Diagnostic Observation Schedule-WPS (ADOS-WPS) 1999 Western Psychological Services Los Angeles, CA
17. M. Mitka Chelation therapy trials halted Journal of the American Medical Association 300 2008 2236
18. D.I. Moel, and K. Kumar Reversible nephrotoxic reactions to a combined 2,3 dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels Pediatrics 70 1982 259 262 (Pubitemid 12089712)
19. A. Mulloy, R. Lang, M. O'Reilly, J. Sigafoos, G. Lancioni, and M. Rispoli Gluten-free and casein-free diets in the treatment of autism spectrum disorders: A systematic review Research in Autism Spectrum Disorders 4 2010 328 339
20. National Research Council C. Lord, J.P. McGee, Educating children with autism 2001 National Academy Press Washington, DC
21. K. Patel, and L. Curtis A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: A prepilot study Journal of Alternative & Complementary Medicine 13 10 2007 1091 1098
22. S.K. Parker, B. Schwartz, J. Todd, and L.K. Pickering Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data Pediatrics 114 2004 793 804 (Pubitemid 41529541)
23. Physicians' Desk Reference Network. (2011, December 19). Concise monograph: Chemet (succimer). Retrieved from: http://www.pdr.net/drugpages/ concisemonograph.aspx?concise=1293#adversereactions
24. B. Rimland, and S. Edelson Autism Treatment Evaluation Checklist: Statistical analyses 2000 Autism Research Institute San Diego, CA
25. J.F. Risher, and S.N. Amler Mercury exposure: Evaluation and intervention: The inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning NeuroToxicology 269 2005 691 699 (Pubitemid 41175902)
26. H. Senel Parents' views and experiences about complementary and alternative medicine treatments for their children with autistic spectrum disorder Journal of Autism & Developmental Disorders 40 2010 494 503
27. R. Simeonsson, and D. Bailey Evaluating programme impact: Levels of certainty D. Mitchell, R. Brown, Early intervention studies for young children with special needs 1991 Chapman and Hall New York, NY 280 296
28. N. Smith The certainty of evidence in health evaluations Evaluation and Program Planning 4 1981 273 278
29. D.E. Stangle, D.R. Smith, S.A. Beaudin, M.S. Strawderman, D.A. Levitksy, and B.J. Strupp Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rates, but produces lasting cognitive impairment in the absence of lead exposure Environmental Health Perspectives 115 2007 201 209
30. P. Sturmey, and A. Fitzer Autism spectrum disorders: Applied behavior analysis, evidence, and practice 2007 Pro-Ed Austin, TX
31. The Editors of the Lancet Retraction - Illeal-lympoid-nodular hyperplasia non-specific colitis, and pervasive developmental disorder in children The Lancet 375 2010 445
32. A.J. Wakefield, S.H. Murch, A. Anthony, J. Linnell, D.M. Casson, and M. Malik Ileallymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children The Lancet 351 1998 637 641 (Pubitemid 28098447)
33. K. Wilson, E. Mills, C. Ross, J. McGowan, and A. Jadad Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine Archives of Pediatrics & Adolescent Medicine 157 2003 628 634
34. L. Wing, and D. Potter Epidemiology of autistic spectrum disorders: Is the prevalence rising? Mental Retardation and Developmental Disabilities 8 2002 151 161 (Pubitemid 36378157)